Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Breast Neoplasms 8Neoplasms 7Uterine Cervical Neoplasms 5Head and Neck Neoplasms 5Prostatic Neoplasms 4Melanoma 4Glioblastoma 4Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Hematologic Neoplasms 3Glioma 3Brain Neoplasms 3Uterine Cervical Dysplasia 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Neuroblastoma 2Lymphedema 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematopoietic and Lymphatic System Neoplasm 2Carcinoma, Squamous Cell 2Atypical Squamous Cells of the Cervix 2Astrocytoma 2Xeroderma Pigmentosum 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Trichothiodystrophy Syndromes 1Tongue Neoplasms 1Testicular Neoplasms 1Teratoma 1

Interventions

lenvatinib 2Temozolomide 2temsirolimus 1penpulimab 1pazopanib 1cabozantinib 1anlotinib 1Vorinostat 1Vinorelbine 1Sirolimus 1Restraint, Physical 1Everolimus 1Absorptiometry, Photon 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraganglioma, Extra-Adrenal × Restraint, Physical × Clear all
NCT02592356 2024-03-05

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

M.D. Anderson Cancer Center

Phase NA Completed
23 enrolled
CNSEndocrine

Paraganglioma, Extra-Adrenal, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡